International
UK initiates review of clinical trials after decreases in recruitment, number of studies
The UK’s once-strong clinical research landscape has been shrinking over the past five years, prompting the government to open an investigation into…

The UK’s once-strong clinical research landscape has been shrinking over the past five years, prompting the government to open an investigation into what can be done to salvage and rebuild.
The UK has appointed former health minister James O’Shaughnessy to review the state of commercial clinical trials in the country and make recommendations based on his findings. The recommendations are expected to be published this spring and will include how to improve and increase clinical trials in 2023 and future years.
From 2017 to 2021, there was a 44% drop in recruitment of patients to commercial clinical trials and a 48% decline in the number of Phase III industry trials initiated in the UK. The UK fell in global ranking from fourth in 2017 for Phase III industry trials to tenth place in 2021, “jeopardising the long-term future of clinical research in the UK,” according to a government review published earlier this year.
Research from the Association of the British Pharmaceutical Industry (ABPI) found that declining industry clinical trial activity caused a deficit of £447 million for the NHS in 2020/2021.
O’Shaughnessy is a senior partner at the consultancy firm Newmarket Strategy, a board member of Health Data Research UK and a former health minister.
“This review will help us to find new ways to conduct commercial clinical trials that will speed up diagnosis, enhance treatment and enable the NHS to deliver world-class care, as well as cementing our position as a life sciences super power,” said health minister Will Quince in a statement.
The announcement of O’Shaughnessy’s review comes after the House of Lords Science and Technology Committee wrote to the Minister of State for Health and Social Care in late January with dire findings from a “short inquiry” into clinical research in the NHS.

The committee recommended that the government address multiple issues including: address the unequal pay for researchers versus full time clinicians; mentorship for clinical academics in less well-off areas; remove incentives for early retirement for NHS consultants; expose doctors-in-training to clinical research in medical school; and set out specific metrics to analyze research performance.
“Without urgent actions from the Government, such as those recommended in our letter, the UK’s clinical research capacity could be permanently diminished, leaving the NHS, patients and the UK economy worse off in the future,” said committee chair Julia Elizabeth King in a statement in January.
The ABPI looked into why the decline is happening and found that the impact of Covid-19 and slow recruitment and study set-up by the NHS is forcing pharmas to conduct trials in other countries. The ABPI made several recommendations last year to jumpstart the life sciences sector, such as prioritizing trials, standardizing contract negotiations between biotechs and their trial sites and reinvest the revenue earned from clinical trials back into research, and training for those working at the sites.

The ABPI also chimed in on the appointment of O’Shaughnessy. The director of research policy, Jennifer Harris, said in a statement that the appointment of O’Shaughnessy is “an important recognition that we need to act decisively to reverse this negative trend.
“The ABPI will work closely with our members and Lord O’Shaughnessy to provide practical solutions on how we can deliver the system-wide reform needed to rebuild our global competitiveness and support NHS patients,” Harris said.
treatment clinical trials covid-19 ukInternational
Fighting the Surveillance State Begins with the Individual
It’s a well-known fact at this point that in the United States and most of the so-called free countries that there is a robust surveillance state in…

International
Stock Market Today: Stocks turn higher as Treasury yields retreat; big tech earnings up next
A pullback in Treasury yields has stocks moving higher Monday heading into a busy earnings week and a key 2-year bond auction later on Tuesday.

- Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.
International
iPhone Maker Foxconn Investigated By Chinese Authorities
Foxconn, the Taiwanese company that manufactures iPhones on behalf of Apple (AAPL), is being investigated by Chinese authorities, according to multiple…

-
Uncategorized10 hours ago
California bill aims to cap crypto ATM withdrawals at $1K per day to combat scams
-
International10 hours ago
Stock Market Today: Stocks turn higher as Treasury yields retreat; big tech earnings up next
-
International12 hours ago
A further examination of the state of the economic tailwind
-
Uncategorized10 hours ago
Bitcoin price must break $31K to avoid 2023 ‘bearish fractal’
-
Uncategorized12 hours ago
Bitcoin ETF to trigger massive demand from institutions, EY says
-
Uncategorized12 hours ago
Crypto community accuses WSJ of exaggerating Hamas crypto funding by 99%
-
International12 hours ago
iPhone Maker Foxconn Investigated By Chinese Authorities
-
Uncategorized10 hours ago
An airline just launched one of the country’s longest domestic flights